Division of Hospital Medicine, Department of Medicine, University of California, San Francisco, 505 Parnassus Ave, PO Box 0131, San Francisco, CA 94143, USA.
JAMA Intern Med. 2013 Jun 24;173(12):1075-81. doi: 10.1001/jamainternmed.2013.714.
Single-site studies have described an association between use of selective serotonin reuptake inhibitors (SSRIs) and adverse outcomes of surgery. Multicenter studies including a broad range of surgical procedures that explore rare outcomes, such as bleeding and mortality, and that account for indications for administration of SSRIs are needed.
To determine whether perioperative use of SSRIs is associated with adverse outcomes of surgery in a national sample of patients.
Retrospective study of patients 18 years or older who underwent major surgery from January 1, 2006, through December 31, 2008, at 375 US hospitals. We used multivariable hierarchical models to estimate associations between SSRI use and our outcomes. Pharmacy data were used to determine whether a patient received an SSRI in the perioperative period.
Three hundred seventy-five US hospitals.
Five hundred thirty thousand four hundred sixteen patients 18 years or older.
Perioperative use of SSRIs.
In-hospital mortality, length of stay, readmission at 30 days, bleeding events, transfusions, and incidence of ventricular arrhythmias.
Patients receiving SSRIs were more likely to have obesity, chronic pulmonary disease, or hypothyroidism (P < .001 for each) and more likely to have depression (41.0% vs 6.2%, P < .001). After adjustment, patients receiving SSRIs had higher odds of in-hospital mortality (adjusted odds ratio, 1.20 [95% CI, 1.07-1.36]), bleeding (1.09 [1.04-1.15]), and readmission at 30 days (1.22 [1.18-1.26]). Similar results were observed in propensity-matched analyses, although the risk of inpatient mortality was attenuated among patients with depression. Sensitivity analyses suggest that, to invalidate our results, an unmeasured covariate would have to have higher prevalence and be more strongly associated with mortality than any covariate included in our models.
Receiving SSRIs in the perioperative period is associated with a higher risk for adverse events. Determining whether patient factors or SSRIs themselves are responsible for elevated risks requires prospective study.
单中心研究已经描述了选择性 5-羟色胺再摄取抑制剂(SSRIs)的使用与手术不良结局之间的关联。需要多中心研究,包括广泛的手术程序,以探索出血和死亡率等罕见结局,并考虑 SSRIs 给药的适应证。
在全国范围内的患者样本中确定围手术期使用 SSRIs 是否与手术不良结局相关。
回顾性研究 2006 年 1 月 1 日至 2008 年 12 月 31 日期间在 375 家美国医院接受主要手术的 18 岁或以上的患者。我们使用多变量层次模型来估计 SSRI 使用与我们的结局之间的关联。药房数据用于确定患者在围手术期是否接受了 SSRIs。
375 家美国医院。
530416 名 18 岁或以上的患者。
围手术期使用 SSRIs。
住院期间死亡率、住院时间、30 天内再入院、出血事件、输血和室性心律失常的发生率。
接受 SSRIs 的患者更有可能患有肥胖症、慢性肺部疾病或甲状腺功能减退症(每项 P <.001),并且更有可能患有抑郁症(41.0%比 6.2%,P <.001)。调整后,接受 SSRIs 的患者住院死亡率(调整后的优势比,1.20 [95%CI,1.07-1.36])、出血(1.09 [1.04-1.15])和 30 天再入院(1.22 [1.18-1.26])的几率更高。在倾向匹配分析中也观察到了类似的结果,尽管抑郁症患者的住院死亡率风险减弱。敏感性分析表明,为了使我们的结果无效,未测量的协变量必须比我们模型中包含的任何协变量具有更高的患病率并且与死亡率的关联更强。
围手术期接受 SSRIs 与不良事件风险增加相关。确定是患者因素还是 SSRIs 本身导致风险增加需要前瞻性研究。